- Investor's Business Daily•3 days ago
Gilead's NASH drug is "clearly active and promising," but Intercept Pharmaceuticals remains one to two years ahead, RBC says.
- Barrons.com•3 days ago
Yesterday, Gilead Sciences (GILD) reported Phase 2 trial data on its NASH treatment that was good enough to move on to Phase 3 (even if everyone wasn't convinced). RBC's Michael Yee and team consider the ...
- Zacks•7 days ago
Intercept's (ICPT) Ocaliva received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval.
Intercept Pharmaceuticals, Inc. (ICPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||30.00 x 100|
|Ask||143.05 x 100|
|Day's Range||131.57 - 139.25|
|52wk Range||89.76 - 217.99|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-9.39|
|Avg Vol (3m)||392,060|
|Dividend & Yield||N/A (N/A)|